Grifols Pauses Canadian Plasma Collection Amid Donor Deaths, Safety Concerns

Spanish healthcare giant Grifols has temporarily halted all plasma collection activities across Canada, a significant move that follows intense public scrutiny and regulatory actions after two donor deaths in Winnipeg. The company attributes the nationwide pause to 'unfounded attention' on its practices, despite Health Canada ongoing investigations into systemic deficiencies at its facilities. This decision casts a spotlight on Canada's reliance on private, for-profit plasma collection and the ethical debates surrounding it. The suspension by Grifols comes after Health Canada identified numerous 'recurring, systemic deficiencies' at several Grifols clinics, including issues with proper donor screening, staff training, and equipment maintenance, even though the regulator found no direct link between the donation process and the donor deaths in October 2025 and January 2026. Critics, including the Canadian Health Coalition, have long argued that paid plasma donation exploits vulnerable populations, urging a return to a fully voluntary public system, echoing lessons from the country's past tainted blood scandal. Grifols, however, plays a crucial role in Canada's plasma supply, which largely relies on imports. While Health Canada assures that this temporary closure will not immediately affect Canada's overall blood supply, the long-term implications for plasma-derived medicine availability remain a key concern. The federal agency states it will collaborate with Grifols to ensure all identified compliance concerns are addressed before any sites can resume operations. This situation is likely to intensify calls for a comprehensive review of Canada's plasma collection policies, pushing for greater transparency and potentially stricter regulations on for-profit clinics to safeguard donor health and the integrity of the national blood system.